✨
AI Summary
- Exploring GLP-1s potential in cancer treatment and Novartis' cardiovascular strategy.
- Lilly's retatrutide shows promise for obesity; cell and gene therapy investment increases.
- Impact of China's new data protection laws on the biopharma business.